Genelux Corp. (GNLX)
2.56
+0.04
(+1.59%)
USD |
NASDAQ |
Oct 02, 16:00
2.56
0.00 (0.00%)
Pre-Market: 20:00
Genelux Shareholders Equity (Quarterly) : 16.11M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 16.11M |
| March 31, 2026 | 22.92M |
| December 31, 2025 | 11.54M |
| September 30, 2025 | 18.59M |
| June 30, 2025 | 23.90M |
| March 31, 2025 | 29.85M |
| December 31, 2024 | 26.27M |
| September 30, 2024 | 33.09M |
| June 30, 2024 | 37.67M |
| March 31, 2024 | 15.08M |
| December 31, 2023 | 19.47M |
| Date | Value |
|---|---|
| September 30, 2023 | 24.03M |
| June 30, 2023 | 22.26M |
| March 31, 2023 | 2.691M |
| December 31, 2022 | -35.78M |
| September 30, 2022 | -32.33M |
| June 30, 2022 | -39.06M |
| March 31, 2022 | -36.54M |
| December 31, 2021 | -33.11M |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | -25.24M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arcutis Biotherapeutics, Inc. | 220.58M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 26.20M |
| Total Liabilities (Quarterly) | 10.09M |
| Debt to Equity Ratio | 0.1502 |
| Current Ratio | 2.394 |
| Net Debt Paydown Yield | -0.09% |